Bar, Yael http://orcid.org/0000-0002-5762-5621
Keenan, Jennifer C.
Niemierko, Andrzej
Medford, Arielle J.
Isakoff, Steven J. http://orcid.org/0000-0002-6677-1014
Ellisen, Leif W. http://orcid.org/0000-0003-0444-7910
Bardia, Aditya
Vidula, Neelima http://orcid.org/0000-0002-5963-7052
Article History
Received: 29 August 2023
Accepted: 25 March 2024
First Online: 11 April 2024
Competing interests
: Individual disclosures for co-authors are as noted below: Y. Bar, J.C. Keenan, A. Niemierko, and S.J. Isakoff declare no potential conflicts of interest. A.J. Medford has consulted for Guardant Health, Illumina, and Natera outside of the submitted work. L.W. Ellisen has consulted for Mersana Therapeutics, Kisoji Biotech, and Astra Zeneca outside of the submitted work. A. Bardia has consulted for Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Phillips, Eli Lilly, and Foundation Medicine. Contracted research/grant to the institution (MGH) has been provided by Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca, and Eli Lilly, all outside of the submitted work. N.Vidula has consulted for AbbVie, OncoSec, Gilead, Aadi, and TerSera and participated in Steering committee for Stemline. Contracted research/grant to the institution (MGH) has been provided by Merck, Daehwa, Radius, Pfizer and Novartis, all outside of the submitted work.